Posted by Michael Wonder on 09 Jul 2026
Lilly Canada receives long-awaited Ebglyss CDA-AMC recommendation as well as pCPA LOI for atopic dermatitis
8 July 2026 - Eli Lilly Canada has officially received a long awaited positive recommendation (reimbursement with conditions) from Canada's Drug Agency for its medicine, Ebglyss, for patients living with moderate-to-severe atopic dermatitis.
Ebglyss received a positive recommendation from L'Institut national d'excellence en santé et services sociaux on 1 August 2024 in Quebec and was subsequently listed on La Régie de l'assurance maladie du Québec, making it available for patients in Quebec.
